Aura Biosciences (AURA) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
5 Aug, 2026Opening remarks and agenda
Meeting called to order by CEO and President, with legal counsel recording minutes.
Meeting held virtually in accordance with bylaws and Delaware law.
Attendees included key finance and legal executives.
Rules of conduct and voting eligibility explained to shareholders.
Specific resolutions to be voted on
Proposal to amend the Certificate of Incorporation to increase authorized common stock from 150 million to 500 million.
Proposal to approve amendment number 1 to the 2021 Stock Option and Incentive Plan.
Corporate governance
Inspector of Election appointed to tabulate votes and confirm quorum.
Quorum established with over 89 million shares represented.
Voting procedures and poll opening/closing times clearly communicated.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Aura Biosciences
- Bel-sar's phase III trial targets vision-preserving tumor control in early choroidal melanoma; data due in 2027.AURA
Morgan Stanley 24th Annual Global Healthcare Conference - Biotech firm seeks to raise up to $500M for R&D and growth, with $200M via Jefferies at-the-market.AURARegistration filing
- Bel-sar shows strong efficacy and safety as a potential first curative therapy for early choroidal melanoma.AURACorporate presentation
- Q2 net loss widened to $45.6M; Phase 3 trial fully enrolled, cash runway to 1H 2029.AURAQ2 2026
- Vote sought to expand authorized shares and amend equity plan for future growth and flexibility.AURAProxy filing
- Vote to expand authorized shares and amend the equity plan to support growth and retention.AURAProxy filing
- Pivotal trials advance in ocular and bladder cancer, targeting large markets with vision-preserving therapies.AURATD Cowen 46th Annual Health Care Conference
- Bel-sar achieved 80% tumor control and 90% vision preservation, advancing to Phase 3.AURAStatus Update
- Bel-sar's dual-action therapy shows strong early efficacy and safety, supporting a shift in bladder cancer care.AURAStatus Update